Skip to main content
Scroll Top
Menu
WHO WE ARE
ABOUT US
TEAM
MANAGEMENT TEAM
INDUSTRIAL ADVISORS
SCIENTIFIC COUNCIL
PARTNERS
R&D
INTRODUCTION
TECH
NEUROSTIMULATION
PHOTOBIOMODULATION
ALZHEIMER
CLINICAL TRIAL
PATHOPHYSIOLOGY
TECHNOLOGY
CONCUSSION
CLINICAL TRIAL
PATHOPHYSIOLOGY
TECHNOLOGY
SOLUTIONS
CLINICAL RESEARCH
PRECLINICAL RESEARCH
CONCUSSION
NEWS
ALL
PRESS ARTICLES
VIDEOS
EVENTS
SCIENTIFIC PUBLICATIONS
ALL
SCIENTIFIC ARTICLES
ORAL COMMUNICATIONS
POSTED COMMUNICATIONS
CONTACT
FAQ
Executive summary
Français
Menu
WHO WE ARE
ABOUT US
TEAM
MANAGEMENT TEAM
INDUSTRIAL ADVISORS
SCIENTIFIC COUNCIL
PARTNERS
R&D
INTRODUCTION
TECH
NEUROSTIMULATION
PHOTOBIOMODULATION
ALZHEIMER
CLINICAL TRIAL
PATHOPHYSIOLOGY
TECHNOLOGY
CONCUSSION
CLINICAL TRIAL
PATHOPHYSIOLOGY
TECHNOLOGY
SOLUTIONS
CLINICAL RESEARCH
PRECLINICAL RESEARCH
CONCUSSION
NEWS
ALL
PRESS ARTICLES
VIDEOS
EVENTS
SCIENTIFIC PUBLICATIONS
ALL
SCIENTIFIC ARTICLES
ORAL COMMUNICATIONS
POSTED COMMUNICATIONS
CONTACT
FAQ
Executive summary
Français
Home
Alzheimer
Clinical Trials on Alzheimer’s Disease (CTAD CHINA)
Most Viewed Posts
Clear Filters
MedInTechs 2026 – Parc Floral de Paris | 9 & 10 March
20 March 2026
REGEnLIFE attempts to prove that advanced phototherapy can cure Alzheimer’s disease
31 October 2024
REGEnLIFE cures inflammatory brain diseases with light
21 February 2025
24 October 2023
Clinical Trials on Alzheimer’s Disease (CTAD CHINA)
Read the article
Jacques Touchon (MD, PhD), University of Montpellier and Guillaume Blivet (MPH), REGEnLIFE, France.
Share this article
alzheimer
Oral Communications
Post navigation
Previous post
The RECOVERY study: first results of a pilot clinical trial to evaluate brain photobiomodulation in acute concussion in sportspeople
Next post
Is brain photobiomodulation therapy safe and effective in treating sportspeople with acute concussion? First results of a pilot clinical trial (RECOVERY STUDY)
Get a Quote
Hidden fields